17-oxo-docosahexaenoic acid

17-oxo-docosahexaenoic acid (17-oxo-DHA) is an electrophilic, α,β-unsaturated keto-derivative of the omega-3 fatty acid docosahexaenoic acid (DHA), generated endogenously by cyclooxygenase-2 (Cox-2) in activated macrophages[3]. It is a bioactive metabolite with documented anti-inflammatory, antioxidant, and cytoprotective properties, acting through multiple mechanisms including inhibition of the NLRP3 inflammasome, suppression of NF-κB-dependent inflammatory reactions, and activation of the Nrf2-dependent antioxidant response[1][3][5]. 17-oxo-DHA has been studied in the context of chronic obstructive pulmonary disease (COPD), where it shows additive anti-inflammatory effects when combined with glucocorticoids like fluticasone propionate, particularly in steroid-resistant inflammation[1][3]. It has also demonstrated protective effects against UVB-induced oxidative cell death, dermatitis, and carcinogenesis in preclinical models[5]. The drug is considered a promising lead compound for developing new therapies for inflammatory and oxidative stress-related conditions, especially where current steroids are ineffective[1][3].

Other names

17-oxo-DHA17-oxo-docosahexaenoic acid